Avalo Therapeutics, Inc. (AVTX) Stock Price & Analysis

Avalo Therapeutics, Inc. (AVTX) closed at USD 7.12 on Wednesday, October 28, 2026, up 5.48% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 6.75; the Oct 28, 2026 session ranged USD 6.66–7.14 on volume of 2,165,697 shares. Market capitalization is $381.85M, with a 52-week range of USD 6.53–24.27 (NCM). Source: Nexqual, retrieved October 29, 2026 at 07:20 UTC.

Also available as compact Markdown for AI agents: nexqual.com/AVTX.md

Key facts (AVTX)

• Analysts: Buy (mean 2.00 on a 1–5 scale) (14 analysts), mean target USD 36.6 (range 10–60).
• Total return with dividends: 1Y -60.5% vs S&P 500 +13.6%; 5Y -99.9% vs S&P 500 +79.8%.
• Next earnings: 2026-11-12, EPS estimate USD -0.55, revenue estimate $0K.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (AVTX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (AVTX)

P/B 0.8x · Earnings yield -26.28%

Analysts (AVTX)

Consensus Buy (mean 2.00 on a 1–5 scale), 14 analysts; mean target USD 36.6 (low 10, high 60).

Rating changes, last 120 days:

Total return (dividends reinvested) (AVTX)

AVTX earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

AVTX recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

AVTX suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 23, 2026.

Companies that name AVTX in their SEC reports

AVTX company outlook (results filed Aug 6, 2026)

• “The Company expects to submit an Investigational New Drug (IND) application in the first half of 2027. • Appointed Ron Philip to its Board of Directors.”

Quoted word-for-word from the SEC 8-K results press release.

AVTX analyst estimates and revisions

AVTX options: expected move

Options price a move of about ±44.2% (±$3.15) by Nov 20, 2026, which includes earnings on Nov 12, 2026. Over the last 8 reports the stock moved ±4.5% on average.

30-day implied volatility 76.5% vs 153.1% realized over the last 30 trading days. Put/call ratio (volume) 3.68. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 07:20 UTC)

Technical Analysis (AVTX)

Nexqual's technical model rates AVTX "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 07:20 UTC.

Analyst Ratings (AVTX)

Wall Street analysts rate AVTX "Buy" based on 14 analysts, with a mean price target of USD 36.6 (range USD 10–60), per Nexqual as of October 29, 2026 at 07:20 UTC.

Earnings (AVTX)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 07:20 UTC.

Financials & Fundamentals (AVTX)

Source: Nexqual, October 29, 2026 at 07:20 UTC.

Financial Health Score (AVTX)

Nexqual rates Avalo Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 07:20 UTC.

Ownership (AVTX)

Source: Nexqual, October 29, 2026 at 07:20 UTC.

Leadership (AVTX)

Avalo Therapeutics, Inc. is led by Garry A. Neil, President, CEO & Director, per Nexqual as of October 29, 2026 at 07:20 UTC.

Major Backers & Investors (AVTX)

Notable institutional backers of Avalo Therapeutics, Inc. include FMR, LLC, Deep Track Capital, Lp, Caligan Partners, LP, according to Nexqual as of October 29, 2026 at 07:20 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 07:20 UTC.

From Avalo Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-23)

Key Strengths & Strategy (as disclosed to the SEC)

• In the United States, the FDA regulates biologics under the Federal Food, Drug, and Cosmetic Act ("FDCA"), the Public Health Service Act, and its implementing regulations.
• State and foreign laws, including for example the European Union General Data Protection Regulation, which became effective May 2018 also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.
• Our success depends in part on our ability to obtain and maintain proprietary protection for the technology and know-how upon which our product candidates are based, to operate without infringing the proprietary rights of third parties and to prevent third parties from infringing our proprietary rights.
• We also rely on trade secrets and proprietary know-how, including manufacturing and formulation know-how, as well as confidentiality agreements and other contractual protections, to protect aspects of our technology and product candidates that may not be patentable or that we elect not to patent.

Partnerships

• We are required to pay Lilly up to $70 million based on the achievement of specified development and regulatory milestones.
• Upon commercialization, we are required to pay sales-based milestones aggregating up to $650 million payable to Lilly and up to $70 million to Leap.

Legal & Regulatory Risks (Item 1A, quoted)

• The FDA may refuse to accept any application for filing, may place a clinical hold on a clinical trial at any stage, or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies.
• The FDA or other regulatory authority may require more information, including additional preclinical or clinical studies to support approval, which may delay or prevent approval and our commercialization plans, or we may decide to abandon the development program.
• We are conducting clinical trials for abdakibart (AVTX-009) at sites in foreign jurisdictions, and the FDA might not accept data from trials conducted in such locations.
• We may fail to achieve our development and regulatory milestones on expected timelines, or at all, which could materially and adversely affect our business, financial condition, results of operations and prospects.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 07:20 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt